This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Inclusion Criteria:
Exclusion Criteria:
jacob.garcia@umoja-biopharma.com425-873-8331
A single dose of UB-VV400 will be administered followed by treatment with rapamycin.
christine.dehner@umoja-biopharma.com
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
Rapamycin in Advanced Cancers
Rapamycin Plus Bevacizumab in Advanced Cancers
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)